Nephrology

Latest News

Advanced-Stage CKD Prevalence Quickly Rising Worldwide: Daily Dose / image credit: ©New Africa/AdobeStock
Advanced-Stage CKD Prevalence Quickly Rising Worldwide: Daily Dose

April 22nd 2024

Your daily dose of the clinical news you may have missed.

Zilebesiran Reduces SBP on Background SOC in Uncontrolled HTN: Daily Dose / image credit: ©New Africa/AdobeStock
Zilebesiran Reduces SBP on Background SOC in Uncontrolled HTN: Daily Dose

April 16th 2024

©pikovit/stock.adobe.com
Advanced-Stage CKD Prevalence Rising Rapidly Worldwide: Multidimensional Modeling Study

April 15th 2024

Zilebesiran Reduces SBP by Up to 14 mm Hg on Background SOC: KARDIA-2 Analysis at ACC.24 Akshay Desai, MD, MPH
Zilebesiran Reduces SBP by Up to 14 mm Hg on Background SOC in Uncontrolled Hypertension: KARDIA-2

April 8th 2024

FDA Approves Aprocitentan (Tryvio) for Treatment-Resistant Hypertension in Landmark Decision
FDA Approves Aprocitentan (Tryvio) for Treatment-Resistant Hypertension in Landmark Decision

March 20th 2024

Latest CME Events & Activities

Navigating Newer Approaches to Managing IgA Nephropathy

April 14, 2024

Register Now!

New York GU™ 17th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

View More

Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy

View More

How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies

View More

Evaluating the Recent Advancements in Chronic Kidney Disease Treatment: A Case-Based Approach to Managing CKD and Related Comorbidities

View More

Expert Illustrations and Commentaries™: Emerging Therapies and Treatment Strategies to Improve Care for Your Patients with Anemia in CKD

View More

Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies

View More

Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?

View More

Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer

View More

Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer

View More

Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?

View More

Community Practice Connections: 7th Annual School of Nursing Oncology™

View More

6th Annual Precision Medicine Symposium: An Illustrated Tumor Board

October 18-19, 2024

Register Now!

Bridging the Care Gap in Anemia in CKD: A Comprehensive Guide to Enhancing Patient Care

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Medical Crossfire®: How Do the Experts Select and Sequence Therapies to Optimize Patient Outcomes and Quality of Life in Advanced Prostate Cancer?

View More

7th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease

View More

41st Annual CFS®: Innovative Cancer Therapy for Tomorrow

View More

GU Tumor Board®: Real World Strategies to Inform Individualized Care in Renal Cell Carcinoma

View More

Medical Crossfire®: Optimizing Care for Patients With Anemia and Chronic Kidney Disease

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy

View More

Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy

View More

More News

© 2024 MJH Life Sciences

All rights reserved.